Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. filed a report describing a virtual key opinion leader event held on June 12, 2026. The event focused on unmet medical needs in postpartum depression and reviewed the clinical profile of the company’s investigational product candidate LPCN 1154.
The related slide presentation was furnished as Exhibit 99.1 and is incorporated by reference. Lipocine notes that a link to the presentation is available on its corporate website, giving investors and clinicians access to the detailed discussion from the event.
Lipocine Inc. held its annual shareholder meeting on June 3, 2026 and approved the Sixth Amended and Restated 2014 Stock and Incentive Plan. The amendment raises individual award limits from 25,000 to 100,000 shares and increases available common stock awards by 400,000 shares, so the plan now authorizes up to 1,000,000 shares in total. Shareholders re-elected four directors and ratified Tanner LLC as independent registered public accountants for the fiscal year ending December 31, 2026. They also approved a say‑on‑pay advisory vote on executive compensation, the amended stock and incentive plan, and an adjournment proposal to continue soliciting votes on these matters.
Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director John W. Higuchi received a grant of derivative securities giving him the right to buy 1,764 shares of common stock at $2.19 per share. These rights vest 100% one year from the grant date and expire on June 3, 2036. Following this award, Higuchi holds rights to purchase a total of 13,290 shares of common stock.
Lipocine Inc. director Jene Jill M. received a grant of stock options covering 1,764 shares of common stock at an exercise price of $2.19 per share. These options vest 100% one year from the grant date and expire on June 3, 2036. Following this grant, the director holds a total of 8,938 derivative securities directly.
Ono Richard Dana reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director Richard Dana Ono received an equity award in the form of derivative rights to buy 1,764 shares of Common Stock at $2.19 per share. This grant is a compensation-related award, not an open-market purchase or sale. The rights vest 100% one year from the grant date and are exercisable until June 3, 2036. After this award, Ono holds derivative rights covering a total of 13,290 shares of Lipocine common stock directly.
Lipocine Inc. filed an 8-K announcing a virtual Key Opinion Leader event focused on postpartum depression and its investigational oral therapy LPCN 1154 (BRLIZIO™). The webcast will be held on Friday, June 12, 2026 at 11:00 AM Eastern Time and feature leading psychiatrists discussing unmet needs in postpartum depression and Phase 3 topline results for LPCN 1154.
LPCN 1154 is an oral formulation of brexanolone designed to deliver bioequivalent exposure to intravenous ZULRESSO® over 48 hours at home, without medical monitoring. In a Phase 3 trial, a subgroup analysis excluding an epidemiologic outlier site showed clinically meaningful, statistically significant efficacy with 100% dosing-period completion and no treatment-related serious adverse events. LPCN 1154 is not yet FDA approved; BRLIZIO™ is a conditionally approved brand name.
Lipocine Inc. filed a current report describing a scientific presentation rather than a financial event. On May 26, 2026, the company presented Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach.
The presentation and a related scientific poster, which summarize results from a placebo-controlled Phase 3 clinical trial in postpartum depression, are included as Exhibits 99.1 and 99.2 to the report and incorporated by reference for full clinical details.
Lipocine Inc. filed a current report describing a scientific milestone for its postpartum depression program. The company announced that Phase 3 clinical data for its oral brexanolone candidate LPCN 1154 have been selected for both oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami.
The oral presentation, titled “Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154,” is scheduled for May 26, 2026. A related poster will be presented on May 27, 2026. Lipocine highlights LPCN 1154 as a non-SSRI, oral formulation of brexanolone designed as a rapid-acting treatment for postpartum depression with potential at-home use and no intensive monitoring requirement, and notes prior data suggesting improved tolerability and low central nervous system depressant side effects.
Lipocine Inc. filed a current report to note that its management will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM.
The attached press release also highlights Lipocine’s oral drug-delivery focused pipeline, which includes candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, as well as its FDA-approved oral testosterone product TLANDO for hypogonadism.
Lipocine Inc. reports a Schedule 13G showing Ikarian Capital and Neil Shahrestani jointly disclose ownership of 508,556 shares of Common Stock, representing 6.3% of the class.
The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts; Ikarian Capital and Mr. Shahrestani state potential indirect beneficial ownership through investment discretion. The 6.3% calculation references 8,025,115 shares outstanding as of April 6, 2026.